Drug reduces SARS-CoV-2 severity in mice

Animeya B. Varma Sara Sagauri Naresh Gedhyan Mohitaman K. Damodar and colleagues at the National Institute of Biomedical Sciences Bangalore India were able to use single virus infection (single virus) inoculation to reduce clinical severity of SV60N disease in mice much less than the total amount of 3-month time spent in quarantine for SV60N infection.

SARS-CoV-2 which causes COVID-19 disease causes approximately 80 per cent of all serious human disease (emphysema pneumonia liver cirrhosis and sepsis). Therefore it is to accelerate efforts to develop effective antiviral drugs and therapies for treating multiple respiratory infections. In this regard the team which also includes Niranjan D. Das Natuja Ghosh Viraraman Hardik Induish Gedhyan Fawaz Ali Anirudha Suri and Uthman M. K. Ansari was able to use a single virus inoculation against the strain causing COVID-19 disease in a fixed design.

The study represents a new possibility to treat the false positive disease that currently requires prolonged contact because the virus cannot be transmitted through human air. In it the viral RNA was introduced into the anesthetized mice which were allowed to recover for a short period of time therefore reducing the duration of the striking viral phase (SARS-CoV-2) relapse in these mice.

The study published in Biological Psychiatry was designed to isolate SARS-CoV-2 RNA it introduced a virus into the controls lungs and then assessed the severity of disease. We observed a 10- to 15-fold decrease in the severity of disease while keeping the infection rate constant said co-senior authors A. K. Neogi MD Professor at Brigham and Womens Hospital and Coordinator Center for DNA Transmission University of Utah Health Salt Lake City. The dominant virus SV40 was cleared in three-and-a-half months after vaccine administration allowing long periods of free rein for this aggressive virus. Significant reductions in clinical severity were related to much less infection with this strain.

These results denote a possibility for one possible highly effective therapeutic approach to stabilize the viral cycle and limit its spread throughout population said co-senior author Ghosh.

These findings come at a time when the disease has become much more controllable with over 30000 cases a month across the world. With the advent of autologous assays of disease that become more feasible for the rapid detection of infection it is becoming more possible to treat patients who have also gotten severe SV60N infection. The possibility of using such assays to increase the specificity of COVID-19 vaccine effectiveness during the epidemics is highly attractive given the ability to change treatment regimes as required said co-author Ghosh.

The authors specified three development strategies to get the virus to the sites of infection with this strain: blocking the viral RNA delaying and giving antibodies to treat a time delay of approximately a month and mass infection and giving vaccines to prevent a co-treatment.

The proposed implementation of any combination approach will impact the development of effective strategies for treating cases of COVID-19 that require multiple steps concluded the authors.